CN108066355A - Purposes of the Nitrous Oxide as treatment neurosis - Google Patents
Purposes of the Nitrous Oxide as treatment neurosis Download PDFInfo
- Publication number
- CN108066355A CN108066355A CN201711461063.7A CN201711461063A CN108066355A CN 108066355 A CN108066355 A CN 108066355A CN 201711461063 A CN201711461063 A CN 201711461063A CN 108066355 A CN108066355 A CN 108066355A
- Authority
- CN
- China
- Prior art keywords
- nitrous oxide
- neurosis
- medicament
- treatment
- gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 title claims abstract description 197
- 239000001272 nitrous oxide Substances 0.000 title claims abstract description 96
- 208000015238 neurotic disease Diseases 0.000 title claims abstract description 89
- 206010029333 Neurosis Diseases 0.000 title claims abstract description 87
- 238000011282 treatment Methods 0.000 title claims abstract description 80
- 239000003814 drug Substances 0.000 claims abstract description 60
- 239000007789 gas Substances 0.000 claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 41
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 38
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000001301 oxygen Substances 0.000 claims abstract description 32
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 32
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910001882 dioxygen Inorganic materials 0.000 claims abstract description 18
- 206010029897 Obsessive thoughts Diseases 0.000 claims abstract description 15
- 208000027520 Somatoform disease Diseases 0.000 claims abstract description 11
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 10
- 230000003442 weekly effect Effects 0.000 claims description 11
- 230000006641 stabilisation Effects 0.000 claims description 6
- 238000011105 stabilization Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 20
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 32
- 201000010099 disease Diseases 0.000 description 30
- 208000024891 symptom Diseases 0.000 description 23
- 230000036506 anxiety Effects 0.000 description 19
- 229960003638 dopamine Drugs 0.000 description 16
- 208000007443 Neurasthenia Diseases 0.000 description 8
- 206010003549 asthenia Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000036651 mood Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 201000001916 Hypochondriasis Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 3
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 3
- 229910003798 SPO2 Inorganic materials 0.000 description 3
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 210000001009 nucleus accumben Anatomy 0.000 description 3
- 208000024335 physical disease Diseases 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010054196 Affect lability Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 210000000467 autonomic pathway Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000002558 medical inspection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000022949 middle ear disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- AEXLPFBSDYGMFP-UHFFFAOYSA-N nitrous oxide Chemical compound [O-][N+]#N.[O-][N+]#N AEXLPFBSDYGMFP-UHFFFAOYSA-N 0.000 description 1
- 235000013842 nitrous oxide Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- -1 that is Chemical compound 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003454 tympanic membrane Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A kind of purposes of Nitrous Oxide for gaseous state inhalant as treatment neurosis, the mixed uniformly gas that the medicament is made of nitrous oxide and oxygen, the mass fraction of nitrous oxide gas is 55%~75% in treatment neurosis medicament containing nitrous oxide, the mass fraction of oxygen gas is 25%~45%, for treating at least one of nervous breakdown, anxiety disorder, neurosis, obsession, somatoform disorder disease, hip；With rapid-action, Small side effects, significant anti-keratin monoclonal antibody effect is a kind of new, safe and effective neurosis orientation treatment.
Description
Technical field
The present invention relates to a kind of purposes of pharmaceutical field more particularly to Nitrous Oxide as treatment neurosis.
Background technology
Neurosis is also known as neurosis or psychoneurosis.International basic coding 43, nosogenesis is unclear, is one
The general name of group phrenoblabia, including neurasthenia, obsession, the burnt chronic diseases marked by deficiency of vital energy, phobia, somatoform disorder etc..《Chinese Spirit
Obstacles classification and the diagnostic criteria third edition》(CCMD-III) descriptive definition of neurosis in：" neurosis is one group and mainly shows
For anxiety, depression, fear, force, the phrenoblabia of hypochondriasis symptom or neurasthenia symptom.This obstacle has certain personality foundation,
Onset is often influenced by factors such as psychology, society, environment.Based on symptom does not have verifiable organic disease, with patient's
Real situation is unbecoming, but patient agonize to existing symptom with it is helpless, insight is complete or substantially complete, the course of disease
More delays.The common disease that neurosis is common clinical frequently-occurring disease and world-wide medical circle and psychological educational circles all pays special attention to
Disease, counts according to the country, this disease accounts for the 10% of internal medicine first visit case, accounts for the 80% of neurology department's first visit case.
From the point of view of the pathogenesis of neurosis, because belonging to psychogenic disorder, it is considered that subtract with individual nervous function
It is weak related with unsound character trait.Mental element serve in morbidity it is important will, it can cause excited and process of inhibition
Imbalance, and the Pathomorphology of nerve fiber in terms of without find affirm change, neurasthenia is most common in neurosis
One kind.Often since doublethink and mental burden are overweight, the reasons such as overstretched and weak after being ill make nerve (especially advanced
Position --- cerebral cortex) hyperactivity hyperkinesia it is nervous, over fatigue, causes imbalance that is excited and inhibiting and generating function is disorderly,
Neurasthenia has occurred.There are many its clinical symptoms, unsystematic, and common is mental fatigue, absent minded, dizzy, note
Power decline, neuroticism, emotional lability, irritability, insomnia are recalled, to environmental stimuli, such as sound, light, especially sensitive and body
The enhancing of interior sensation, such as can feel cardiovascular beating or undue concentration is noted that the various change of body and generates each
Kind hypochondriacal idea, such as doubt raw brain tumor, heart disease, fear that mental disease can be developed into.Neurosis is caused by psychological factor
, be substantially it is bad in terms of subjective sensation, without corresponding organic lesion.It shows as party's mass society and adapts to energy
It tries hard to keep and holds normal or influence little；There is good insight, have sufficient impression to the discomfort of oneself, generally can actively seek medical advice.
Neurasthenia：Neurasthenia belongs to one kind of mental disease, be a kind of spirit easily it is excited and it is mental it is easily tired,
The neurotic disorder for worry and the psychology physiological symptom of being often in a bad mood.Neurasthenia is since cerebral nerve activity is chronically at tightly
The state of opening, one group for causing brain excitement and inhibition functional disturbance and generating is with symptoms such as spiritual easily excitement, brain emotional instabilities
With the characteristics of nervous function sexual dysfunction.There is the easily excited and mental easily tired phenomenon of spirit, be often accompanied by mood worry, irritability,
Sleep-disorder, muscle tone pain etc.；These symptoms cannot be attributed to brain, physical disease and other mental illnesses.It is light during symptom
Shi Chong, fluctuation is related with psychosocial factor, and the course of disease is delayed more.
Anxiety disorder：Also known as anxiety neurosis is the most common type in neurosis this major class disease, with anxiety feelings
Thread is main feature.Chronic anxiety, i.e. generalized anxiety disorder and acute anxiety attack, i.e. two kinds of forms of panic disorder can be divided into.It is burnt
Consider disease to be mainly shown as：The nervous worry of no clear and definite objective objects, is on tenterhooks, and also has vegetative nerve symptom, such as palpitaition, hand
It trembles, perspire, frequent micturition etc..Pay attention to distinguishing normal anxiety, if anxiety severity and objective fact or situation are not substantially inconsistent,
Or the duration is long, then may be pathologic anxiety.It is all secondary to bodies such as hypertension, coronary heart disease, hyperthyroidism
The anxiety of body disease should be diagnosed as anxious syndrome.
Neurosis:Also known as phobia or phobic anxiety obstacle.It is a kind of nerve that clinical manifestation is wanted based on terrified symptom
Disease.Be it is a kind of using undue and unreasonably fear extraneous object or situation as main neurosis, patient to some specific objects or
Situation generates strong and unnecessary frightened mood, and with apparent anxiety and autonomic nerve symptom, and actively take back
The mode kept away releases this uneasiness.Patient knows that frightened mood is unreasonable, unnecessary perfectly well, but is unable to control, and patient strongly returns
The object or situation or go to endure with fear that refuge is feared, so that influencing its normal activity.Frightened object can be single
One or it is a variety of, such as animal, square, closed chamber, ascend a height or social activity.This disease is occupied with adolescence and senile onset person
More, women is more common.Often with significant anxiety and autonomic nerve symptom during panic attack.
Obsession is called compulsive disorder：Obsession belongs to a type of anxiety disorder, be one group with force thinking and
Compulsive behavior is the neuropsychiatric disease of main clinical manifestation, and feature is forced and deposited with counter for conscious force, some millis
Idea that is meaningless, even running counter to oneself wish or impulsion again and again invade the daily life of patient.Though patient experiences this
A little ideas or impulsion are derived from itself, strongly resist, but are unable to control always, and patient also recognizes the exception of obsessive symptoms
Property, but can not break away from.The strong conflict of the two makes it feel huge anxiety and pain, influences study and work, human communication very
To daily life.
Data statistics in recent years shows that the incidence of obsession is constantly soaring, there is that researches show that forced in general population
The lifetime prevalence of disease is 1%~2%, and about 2/3 patient fell ill before 25 years old.Obsession is because of its onset morning, protracted course etc.
Feature often causes patient's social function and quality of life extreme influence, the global disease tune that the World Health Organization (WHO) is done
Middle discovery is looked into, obsession has become one of 20 kinds of diseases for causing Disease Spectrum most heavy for 15~44 years old in Chinese middle-aged adults.
Somatoform disorder：It is a kind of god characterized by enduringly worrying or believe the dominant idea of various somatizations
Through disease.For patient because these symptoms are seen a doctor repeatedly, the negative explanation with doctor of various medical inspections cannot give up its doubt.I.e.
Make that occasionally there are property, degree or its pains and dominant idea that certain physical obstacle can not explain told symptom.It is often accompanied by
Anxiety or depressive emotion.Although the generation of symptom and lasting and offending life event, difficulty or closely related, the disease that conflicts
People often denies the presence of psychological factor.This obstacle men and women has, and is the chronic fluctuation course of disease.
Hip is called hypochondriacal disorder：Hip is also known as hypochondriacal neurosis, is classified as at present in somatoform disorder,
It refers mainly to patient and worries or believe that, with one or more severe physical diseases, patient tells somatization, sees a doctor repeatedly, although through
Medical inspection display is negative repeatedly and doctor gives the medical explanation of no corresponding disease and can not give up the misgivings of patient, often
With anxiety or depression.This disease was mostly fallen ill before 50 years old, and body is different from somatoform disorder without apparent household characteristics, is slow
Property the fluctuation course of disease, men and women can occur.
So exploring a kind of curative effect affirmative, Small side effects, effect is fast, hommization, the comfortable and anti-nerve that can work immediately
Disease therapy be very it is necessary to.
The content of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of use of Nitrous Oxide as treatment neurosis
On the way, i.e., purposes of a kind of nitrous oxide as treatment neurosis, main component nitrous oxide can play treatment immediately
Effect, the therapy of safe and convenient.A kind of new opplication of nitrous oxide is provided, nitrous oxide is controlled applied to neurosis
It treats, which has the advantages that quick-acting, safe, comfortable, no pain, simplicity, economy, can substitute buspirone anxiolytic drugs.
The technical solution adopted by the present invention to solve the technical problems is：
A kind of purposes of Nitrous Oxide as treatment neurosis.
Optimal, the concentration of nitrous oxide is 55%~75% in the medicament, i.e., the matter of nitrous oxide in medicament
It is 55%~75% to measure fraction.
Optimal, the medicament is gaseous state inhalant.
Optimal, the medicament further includes oxygen, and the concentration of the oxygen is 25%~45%, the i.e. mass fraction of oxygen
For 25%~45%.
Optimal, the mixed uniformly gas that the medicament is made of nitrous oxide and oxygen contains an oxidation two
The mass fraction of nitrous oxide gas is 55%~75% in the treatment neurosis medicament of nitrogen, the quality point of oxygen gas
Number is 25%~45%；The mass fraction of nitrous oxide gas is 55%~75% i.e. in medicament, oxygen gas in mixed gas
The mass fraction of body is 25%~45%.
Optimal, the medicament is to be uniformly mixed nitrous oxide and oxygen, wherein nitrous oxide gas
Mass fraction is 55%~75%, and the mass fraction of oxygen gas is 25%~45%；Nitrous oxide gas i.e. in medicament
Mass fraction is 55%~75%, and the mass fraction of oxygen gas is 25%~45% in mixed gas；Or the medicament is
Nitrous oxide and oxygen are passed through simultaneously, and treats the quality of nitrous oxide gas in the mixed gas of nitrous oxide and oxygen
Fraction stabilization is 55%~75%, and the mass fraction stabilization of oxygen gas is 25%~45%, i.e., nitrous oxide gas in medicament
The mass fraction of body is 55%~75%, starts to make when the mass fraction of oxygen gas is 25%~45% in mixed gas
With side cobordant is used.
Optimal, the medicament treats soakage as 1~200L every time.
Optimal, the medicament treats soakage as 1~70L every time.
Optimal, 1~7 treatment is carried out weekly, i.e., uses 1~7 medicament weekly.
Optimal, the neurosis is nervous breakdown, anxiety disorder, neurosis, obsession, somatoform disorder
At least one of disease, hip.
As shown from the above technical solution, purposes of the Nitrous Oxide provided by the invention as treatment neurosis,
Main component nitrous oxide, nitrous oxide be widely used in acute injury early stage analgesia and required analgesia time it is shorter
Operation and other invasive medical care precesses in drug, have many advantages, such as safely, effectively, simplicity, as anodyne, to anxiety disorder
Treatment also have significant effect, on the one hand by acting on central nervous system, promote dopamine D_2 receptors, supplement neurosis is suffered from
Person causes the release of dopamine to inhibit, another aspect neurosis causes general malaise, and mood is low because cerebral neurotransmitters are disorderly
Fall, self-negation, fear, the pain of anxiety muscle weakness, anxiety of releiving, reduce serious neurological disease suicide tendency
Deng so that Patients with Neurosis is during the entire course for the treatment of, pleasant, safety, optimistic positive partner treatment, finally helps neurosis
Patient walks out haze.Nitrous oxide has rapid-action, Small side effects, significant nerve as treatment neurosis medicament
Weak, neurosis, anxiety disorder, obsession and hip therapeutic effect are safe and convenient to use by clinical test.
Specific embodiment
The technical solution of inventive embodiments is further elaborated.
A kind of main component nitrous oxides of the Nitrous Oxide of the present invention as the purposes for treating neurosis be
A kind of natural component in air, concentration is about in 0.5ppm, nitrogen oxides, including the nitrous oxide generated by denitrogenation
(N2O) also known as laughing gas, that is, nitrous oxide (nitrous oxide), it is made of Priestpley within 1779, Davy has found within 1779
There is anesthetic effect, wells in 1844 anaesthetizes for having tooth pulled out, and is still now one of widely applied inhalation anesthetic.Nitrous oxide
It is the neurotransmitters of a definite gas for a kind of neurotransmitter.
Many different types of drug abuse withdrawal states, nitrous oxide can effectively be treated by being proved to nitrous oxide
It may be related with Mesolimbic dopamine system interaction to withdrawal from abuse of drugs state.Evidence suggests in withdrawal state
The release for dopamine occur inhibits.Therefore, researcher assumes that the primary treatment effect of nitrous oxide is adjusted to have the ability
Dopamine system in nucleus accumbens septi, so as to correct the serious deficit of the dopamine D_2 receptors in withdrawal state, for nitrous oxide
Treatment neurosis may also be completed by above-mentioned mechanism.
Dopamine (C6H3(OH)2-CH2-CH2-NH2) secreted by intracerebral, the neural urmaterie dopamine of midbrain
(Dopamine), then directly affect the mood of people, theoretically from the point of view of, increase this substance, with regard to people can be allowed excited, dopamine
(Dopamine) it is a kind of key neurotransmitter in hypothalamus and pituitary, the mood of people, while maincenter god can be directly affected
It is influenced again by mental element through the dopamine concentration in system.The substance of this mystery can make one feeling excited, and transmission is opened
The information of heart excitement.
In view of this, by the study found that nitrous oxide gas may act on central nervous system, being to adjust nucleus accumbens septi
In dopamine system, promote the release of dopamine, so as to supplement Patients with Neurosis because spirit, psychology, physiology, personality, something lost
There is cerebral neurotransmitters disorder in the factors such as biography, cause the excited imbalance with process of inhibition, the release of dopamine is caused to inhibit,
That is because the release of dopamine is suppressed, cause body release more so as to cause the disorder of Patients with Neurosis cerebral neurotransmitters
Bar amine deficiency, nitrous oxide is for dopamine system that the treatment of neurosis is by Central nervous system nucleus accumbens septi region
Adjustment promotes dopamine D_2 receptors, and supplement Patients with Neurosis causes the release of dopamine to inhibit because cerebral neurotransmitters are disorderly,
So as to reach therapeutic purposes.
Research simultaneously shows that nitrous oxide has significant anxiolytic effect, and for the treatment of neurosis, neurosis is suffered from
Person is most of with anxiety, and the significant angst resistance effect of nitrous oxide can also alleviate Patients with Neurosis because diseased simultaneously
It is caused have a sleepless night, constrain, anxiety, fear, self-negation, pessimism, pain caused by self-closing general malaise, anxiety of releiving feelings
Thread reduces suicide etc. of serious neurological disease patient so that Patients with Neurosis during entire rehabilitation, loosen, comfortably, it is happy
It sees, positive treatment, to realize the purpose for the treatment of neurosis.
Embodiment 1：
A kind of purposes of Nitrous Oxide as treatment neurosis, medicament are gaseous state inhalant, an oxygen in medicament
The concentration for changing phenodiazine is 55%~75%, i.e., the mass fraction of nitrous oxide is 55%~75% in medicament.Treatment nerve declines
At least one of weak disease, anxiety disorder, neurosis, obsession, somatoform disorder disease, hip.
Embodiment 2：
A kind of purposes of Nitrous Oxide as treatment neurosis, medicament are gaseous state inhalant, and medicament includes one
Nitrous oxide and oxygen, the concentration of nitrous oxide is 55%~75% in medicament, i.e., the quality of nitrous oxide is divided in medicament
Number is 55%~75%, and the concentration of oxygen is 25%~45% in medicament, i.e., the mass fraction of oxygen is 25%~45%.Treatment
At least one of nervous breakdown, anxiety disorder, neurosis, obsession, somatoform disorder disease, hip.
1~7 treatment is carried out weekly, i.e., weekly using 1~7 medicament, medicament treats soakage as 1~200L every time.
Embodiment 3：
A kind of purposes of Nitrous Oxide as treatment neurosis, medicament are gaseous state inhalant, and medicament is by one
The mixed uniformly gas of nitrous oxide and oxygen composition is to be formed filling after nitrous oxide and the uniform mixing of oxygen, contains
The mass fraction for having nitrous oxide gas in the treatment neurosis medicament of nitrous oxide is 55%~75%, oxygen gas
The mass fraction of body is 25%~45%；The mass fraction of nitrous oxide gas is 55%~75% i.e. in medicament, gaseous mixture
The mass fraction of oxygen gas is 25%~45% in body.Treat nervous breakdown, anxiety disorder, neurosis, obsession, body shape
At least one of formula disfunction, hip.
1~7 treatment is carried out weekly, i.e., weekly using 1~7 medicament, medicament treats soakage as 1~70L every time.
Embodiment 4
A kind of purposes of Nitrous Oxide as treatment neurosis, medicament are gaseous state inhalant, and medicament is simultaneously
Nitrous oxide and oxygen are passed through, and treats the mass fraction of nitrous oxide gas in the mixed gas of nitrous oxide and oxygen
Stablize 55%~75%, the mass fraction stabilization of oxygen gas is 25%~45%, i.e., nitrous oxide gas in medicament
Mass fraction is 55%~75%, is begun to use when the mass fraction of oxygen gas is 25%~45% in mixed gas,
Side cobordant is used.
Treat at least one in nervous breakdown, anxiety disorder, neurosis, obsession, somatoform disorder disease, hip
Kind.1~7 treatment is carried out weekly, i.e., weekly using 1~7 medicament, medicament treats soakage as 1~70L every time.
Embodiment 5：
A kind of purposes of Nitrous Oxide as treatment neurosis, medicament are gaseous state inhalant, and feeder is same
When connected with the gas bomb of two 1~20L, one be nitrous oxide gas cylinder, one be oxygen cylinder, on gas inhalation device
There is the conciliation knob for adjusting gas concentration, after nitrous oxide gas concentration is arranged to 55%~75%, open an oxygen respectively
Change phenodiazine and oxygen cylinder gas outlet valve, two kinds of gases import threeway mixed gas pipeline simultaneously, and gas concentration sensor can be accurate
The really mixed gas concentration in measurement three-way pipeline after nitrous oxide and oxygen mix, when nitrous oxide in feeder
Concentration is accurately shown as 55%~75% on computer display screen, and when the concentration of oxygen is 25%~45%, i.e. feeder
The mass fraction of middle nitrous oxide gas is 55%~75%, the mass fraction of oxygen gas be 25%~45% when
It waits, gas concentration stabilization to be mixed starts treatment application in above range.
Treat at least one in nervous breakdown, anxiety disorder, neurosis, obsession, somatoform disorder disease, hip
Kind.1~7 treatment is carried out weekly, i.e., weekly using 1~7 medicament, medicament treats soakage as 1~70L every time.
Pharmacodynamics clinical tests of the Nitrous Oxide of the present invention as the purposes for the treatment of neurosis：
Under the assistance and support of the units such as hospital of public security narcotic house of Yinchuan City, using a kind of above-mentioned Nitrous Oxide
As the purposes and its therapy for the treatment of neurosis, purpose observe nitrous oxide to Patients with Neurosis observation of curative effect and
Adverse reaction.
1. research object：
The pharmacodynamics clinical test of nitrous oxide of the present invention:
All cases meet the Chinese Spirit Disease Diagnosis Standards of CCMD -3, exclude severe physical disease and other are serious
Mentally disturbed, exclude intestinal obstruction, air embolism, pneumothorax, epilepsy, the respiratory diseases patient such as obstructive respiration and it is acute on
Respiratory tract infection excludes the ear nose larynx organ patients such as nasosinusitis, middle ear diseases, eardrum transplanting, excludes previously have abuse antalgesic
Object history patient and pregnant woman.
2. research method：Ethics official written reply number：Peaceful medical university ethics 2016-150.
Selection is extracted in Yinchuan hospital of public security narcotic house to be met《Chinese Spirit Obstacles classification and diagnostic criteria the 3rd edition》Nerve
Disease patient 60, patient is male, 16~62 years old age, 36.8 years old average, the course of disease 4 months~8 years.Neurasthenia 21,
Obsessive-compulsive neurosis 18, anxiety neurosis 9, phobic neurosis 6, depressive neurosis 3, hypochondriacal neurosis
3, the treatment of nitrous oxide therapy is given, aids in mental health guidance, and observation analysis its effect.
Using neural Remedies of the invention：I.e. Patients with Neurosis is taken to therapeutic room, gets ready with object, to nerve before treatment
Disease patient carries out indices assessment, assesses and completes, and meets indication person and every observation before treatment is gathered by designated recorder person
Index instructs test group subject by the fixed research group membership, and subject takes clinostatism, is opened and supplied by researcher
Device by knob valve, adjusts the gas concentration of nitrous oxide and oxygen, starts after concentration stabilization is accurate as addict received treatment
Operation treatment, subject voluntarily fix mask, after oxygen sucks 200 liters, suck gas 1-200 liters, then give 200 liters of oxygen
Sucking carries out Patients with Neurosis every mark referred to again after the completion for the treatment of and assesses and record, implement treatment the 1-7 days, 1 day
Treatment 1 time；Implement treatment the 8-14 days, treatment in 2 days is once；It treats 1 time implement treatment 3 days the 15-20 days；Implement treatment
21-60 days, only take every 10 days psychological rehabilitations dredge treatment once, after treatment end, the 60th day, the 90th day tracking follow-up.
3. observation index：
(1) primary observation index：Curative effect determinate standard and result
It is effective：Clinical symptoms and sign complete incidence graph；
Effectively：Symptom and sign are alleviated or are obviously improved；
It is invalid：It is not improved with comparison before treatment.
As a result：Effective 35, effective 21, invalid 4, total effective rate 93%.
(2) secondary observation index：HR, BP, SPO2, blood routine, routine urinalysis, electrocardiogram, liver function and curer
Impression and adverse reaction, such as nauseous, drowsiness, noise sense, dizziness, bad dream, memory loss, hyperventilation.
After nitrous oxide is treated, the equal complete incidence graph of symptom of Patients with Neurosis, therapeutic agent of the present invention is pretherapy and post-treatment
Comparison, significant effect, it is in be decreased obviously trend that the symptom of entire therapeutic process Patients with Neurosis, which is, by the treatment of 20 days, god
Therefrom severe is to significantly alleviating for clinical symptoms through disease patient, the rehabilitation effect of 60 days follow-up Patients with Neurosis after treatment end
Fruit is cured or 35 effective, is improved 19, total effective rate 90%, and for treatment end after 90 days, follow-up, which is cured and improved, amounts to 56
People, total effective rate 93%.
Conclusion：60 patients, 56 patient symptoms substantially eliminate, and present invention treatment neurosis works well, and patient easily connects
By.
Adverse reaction and laboratory examination results：
Diarrhea 3, alleviates after symptomatic treatment.Blood routine, routine urinalysis, electrocardiogram, liver function test are in normal range (NR).
The influence of vital sign in therapeutic process：
It is not statistically significant in terms of the pretherapy and post-treatment heart rate for the treatment of group patient, systolic pressure, diastolic pressure and SpO2 that (P values are equal
More than 0.05).Heart rate, systolic pressure, diastolic pressure and SPO2 compare after treatment group patient treatment, and difference is statistically significant, and (P values are equal
Less than 0.001).Diastolic blood pressure values are close to (P after two groups of patients treatment>0.05), heart rate, systolic pressure and SPO2 comparison among groups differences have
Statistical significance (P<0.05 or P<0.01).
The oxygen saturation situation for the treatment of group and control group is as shown in the table,
Conclusion：Nitrous Oxide of the present invention are treated as the purposes for the treatment of neurosis for neurosis
With rapid-action, Small side effects, significant anti-keratin monoclonal antibody effect is a kind of new, safe and effective neurosis treatment side
Method.
Nitrous oxide has significant anxiolytic effect, for the treatment of neurosis, the most of all companions of Patients with Neurosis
There is anxiety, the significant angst resistance effect of nitrous oxide can also alleviate mistake of the Patients with Neurosis caused by because of illness simultaneously
Sleep, constrain, anxiety, fear, self-negation, pessimism, pain caused by self-closing general malaise, anxiety of releiving reduces tight
Suicide etc. of weight Patients with Neurosis so that Patients with Neurosis during entire rehabilitation, loosen, comfortably, it is optimistic, positive
Treatment, to realize the purpose for the treatment of neurosis.
Claims (10)
1. a kind of purposes of Nitrous Oxide as treatment neurosis.
2. purposes of the Nitrous Oxide according to claim 1 as treatment neurosis, it is characterised in that：Institute
The concentration of nitrous oxide in medicament is stated as 55%~75%, i.e., in medicament the mass fraction of nitrous oxide be 55%~
75%.
3. purposes of the Nitrous Oxide according to claim 2 as treatment neurosis, it is characterised in that：Institute
Medicament is stated as gaseous state inhalant.
4. purposes of the Nitrous Oxide according to claim 3 as treatment neurosis, it is characterised in that：Institute
It states medicament and further includes oxygen, the concentration of the oxygen is 25%~45%, i.e., the mass fraction of oxygen is 25%~45%.
5. purposes of the Nitrous Oxide according to claim 4 as treatment neurosis, it is characterised in that：Institute
State the mixed uniformly gas that medicament is made of nitrous oxide and oxygen, the treatment neurosis containing nitrous oxide
The mass fraction of nitrous oxide gas is 55%~75% in medicament, and the mass fraction of oxygen gas is 25%~45%；I.e.
The mass fraction of nitrous oxide gas is 55%~75% in medicament, and the mass fraction of oxygen gas is 25% in mixed gas
~45%.
6. purposes of the Nitrous Oxide as treatment neurosis according to any one in claim 3~5,
It is characterized in that：The medicament is to be uniformly mixed nitrous oxide and oxygen, wherein the quality of nitrous oxide gas
Fraction is 55%~75%, and the mass fraction of oxygen gas is 25%~45%；The quality of nitrous oxide gas i.e. in medicament
Fraction is 55%~75%, and the mass fraction of oxygen gas is 25%~45% in mixed gas；Or the medicament is simultaneously
Nitrous oxide and oxygen are passed through, and treats the mass fraction of nitrous oxide gas in the mixed gas of nitrous oxide and oxygen
Stablize 55%~75%, the mass fraction stabilization of oxygen gas is 25%~45%, i.e., nitrous oxide gas in medicament
Mass fraction is 55%~75%, is begun to use when the mass fraction of oxygen gas is 25%~45% in mixed gas,
Side cobordant is used.
7. purposes of the Nitrous Oxide according to claim 6 as treatment neurosis, it is characterised in that：Institute
It states medicament and treats soakage every time as 1~200L.
8. purposes of the Nitrous Oxide according to claim 7 as treatment neurosis, it is characterised in that：Institute
It states medicament and treats soakage every time as 1~70L.
9. purposes of the Nitrous Oxide according to claim 8 as treatment neurosis, it is characterised in that：Often
1~7 treatment of Zhou Jinhang, i.e., use weekly 1~7 medicament.
10. purposes of the Nitrous Oxide according to claim 9 as treatment neurosis, it is characterised in that：Institute
Neurosis is stated as at least one in nervous breakdown, anxiety disorder, neurosis, obsession, somatoform disorder disease, hip
Kind.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711461063.7A CN108066355A (en) | 2017-12-28 | 2017-12-28 | Purposes of the Nitrous Oxide as treatment neurosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711461063.7A CN108066355A (en) | 2017-12-28 | 2017-12-28 | Purposes of the Nitrous Oxide as treatment neurosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108066355A true CN108066355A (en) | 2018-05-25 |
Family
ID=62156166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711461063.7A Pending CN108066355A (en) | 2017-12-28 | 2017-12-28 | Purposes of the Nitrous Oxide as treatment neurosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108066355A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1829522A (en) * | 2003-07-30 | 2006-09-06 | 液体空气卫生(国际)公司 | Inhalable gaseous medicine based on xenon and nitrous oxide |
| CN101272683A (en) * | 2005-04-07 | 2008-09-24 | 海蒂亚姆公司 | Methods for the treatment of substance abuse and dependence |
| CN101815438A (en) * | 2007-08-06 | 2010-08-25 | 辛诺西亚治疗公司 | Method of treating dependency |
| CN104337830A (en) * | 2013-11-12 | 2015-02-11 | 余建强 | Addiction-free inhalation rehabilitation agent |
| CN105193838A (en) * | 2015-09-15 | 2015-12-30 | 宁夏恩多芬科技有限公司 | New technology of nitrous oxide quick-acting drug treatment |
-
2017
- 2017-12-28 CN CN201711461063.7A patent/CN108066355A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1829522A (en) * | 2003-07-30 | 2006-09-06 | 液体空气卫生(国际)公司 | Inhalable gaseous medicine based on xenon and nitrous oxide |
| CN101272683A (en) * | 2005-04-07 | 2008-09-24 | 海蒂亚姆公司 | Methods for the treatment of substance abuse and dependence |
| CN101815438A (en) * | 2007-08-06 | 2010-08-25 | 辛诺西亚治疗公司 | Method of treating dependency |
| CN104337830A (en) * | 2013-11-12 | 2015-02-11 | 余建强 | Addiction-free inhalation rehabilitation agent |
| CN105193838A (en) * | 2015-09-15 | 2015-12-30 | 宁夏恩多芬科技有限公司 | New technology of nitrous oxide quick-acting drug treatment |
Non-Patent Citations (1)
| Title |
|---|
| GILLMAN M. A.，ET AL.: ""Psychotropic Analgesic Nitrous Oxide For Acute Cocaine Withdrawal In Man"", 《INTERNATIONAL JOURNAL OF NEUROSCIENCE》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saletu-Zyhlarz et al. | Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone | |
| Chen et al. | Effect of acupressure on nausea, vomiting, anxiety and pain among post-cesarean section women in Taiwan | |
| Gift | Dyspnea | |
| Martin-Sanchez et al. | Effects of 12-week inspiratory muscle training with low resistance in patients with multiple sclerosis: a non-randomised, double-blind, controlled trial | |
| Ebben et al. | Moderating laboratory adaptation with the use of a heart-rate variability biofeedback device (StressEraser®) | |
| Robinson et al. | Oxford handbook of respiratory nursing | |
| Wang et al. | Efficacy and safety of penetration acupuncture on head for acute intracerebral hemorrhage: a randomized controlled study | |
| Ciocan et al. | Impact of wearing a surgical mask on respiratory function in view of a widespread use during COVID-19 outbreak. A case-series study | |
| Sayed et al. | The effect of relaxation techniques on quality of sleep for patients with end stage renal failure undergoing hemodialysis | |
| Mohamed et al. | The effect of Buteyko breathing technique among patients with bronchial asthma: Comparative study | |
| Smits et al. | The effects of acute exercise on CO2 challenge reactivity | |
| Kashalikar | Effect of Kapalbhati pranayama on waist and hip circumference | |
| Harit et al. | Randomized, Double-Blind, Placebo-Controlled, Clinical Study of Passiflora incarnata in Participants With Stress and Sleep Problems | |
| Yuan et al. | Frailty-originated early rehabilitation reduces postoperative delirium in brain tumor patients: results from a prospective randomized study | |
| Qin et al. | Effectiveness of hand self-shiatsu to improve sleep following sport-related concussion in young athletes: a proof-of-concept study | |
| Villareal et al. | Effect of Buteyko method on asthma control and quality of life of Filipino adults with bronchial asthma | |
| Donesky | Dyspnea, cough, and terminal secretions | |
| He et al. | Evaluation of the efficacy and safety of intradermal needle therapy on the sleep quality of patients following laparoscopic hysterectomy: study protocol for a randomized controlled trial | |
| CN108066355A (en) | Purposes of the Nitrous Oxide as treatment neurosis | |
| Heyse-Moore | On dyspnoea in advanced cancer | |
| Moustafa Abdallah Elpasiony et al. | Postoperative Nausea, Vomiting, and Retching in Orthopedic Patients: The Influence of Deep Breathing Exercise | |
| Badau et al. | The Relationship between Sleep Quality and Posture: A Study on University Students | |
| Gupta et al. | Ujjayi pranayama in hypothyroidism: A scoping review | |
| RU2769783C1 (en) | Use of krypton in therapy of somatoform mental disorders | |
| Moran et al. | Systems releasing action therapy with alcoholics: An experimental evaluation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180525 |
|
| RJ01 | Rejection of invention patent application after publication |